It is the first to estimate the effectiveness of a third dose of Pfizer-BioNTech mRNA COVID-19 vaccine against severe outcomes with adjustment for various possible confounders, including comorbidities and behavioural factors. A recent clinical trial conducted by BioNTech included a smaller sample size and did not estimate the third-dose’s effects for more severe outcomes.
